DalsnaFinance

Twist Bioscience Corp $TWST

Health Care

Russell 2000 California
Create a scorecard
$135.47
-13.66 (-9.16%)
As of Oct 22, 2026, 9:30 PM EDT · cached
Price history
Loading chart…

Twist Bioscience Corp (TWST) is trading down at $135.47 (-9.16%), as of the latest quote. It is a Russell 2000 constituent in the Health Care sector.

IPO: October 31, 2018 · $14.00 offering · NASDAQ · View IPO details →

Twist Bioscience Corp revenue & net income history (FY2017–FY2025)

RevenueNet incomeNet margin (right axis, %)
$376.6M$79.4M−$217.9MFY2017 revenue: $10.8MFY2017 net income: −$59.3M · Net margin −550.8%'17FY2018 revenue: $25.4MFY2018 net income: −$71.2M · Net margin −280.2%'18FY2019 revenue: $54.4MFY2019 net income: −$107.7M · Net margin −198.0%'19FY2020 revenue: $90.1MFY2020 net income: −$139.9M · Net margin −155.3%'20FY2021 revenue: $132.3MFY2021 net income: −$152.1M · Net margin −114.9%'21FY2022 revenue: $203.6MFY2022 net income: −$217.9M · Net margin −107.0%'22FY2023 revenue: $245.1MFY2023 net income: −$204.6M · Net margin −83.5%'23FY2024 revenue: $313.0MFY2024 net income: −$208.7M · Net margin −66.7%'24FY2025 revenue: $376.6MFY2025 net income: −$77.7M · Net margin −20.6%'25−72.3%−50%0%50%FY2017 net margin: −550.8% (off the scale, which stops at −72.3%)FY2018 net margin: −280.2% (off the scale, which stops at −72.3%)FY2019 net margin: −198.0% (off the scale, which stops at −72.3%)FY2020 net margin: −155.3% (off the scale, which stops at −72.3%)FY2021 net margin: −114.9% (off the scale, which stops at −72.3%)FY2022 net margin: −107.0% (off the scale, which stops at −72.3%)FY2023 net margin: −83.5% (off the scale, which stops at −72.3%)FY2024 net margin: −66.7%FY2025 net margin: −20.6%
Twist Bioscience Corp annual financial statements
FY2017Sep 2017FY2018Sep 2018FY2019Sep 2019FY2020Sep 2020FY2021Sep 2021FY2022Sep 2022FY2023Sep 2023FY2024Sep 2024FY2025Sep 2025
Income statement
Revenue$10.8M$25.4M$54.4M$90.1M$132.3M$203.6M$245.1M$313.0M$376.6M
Growth (year over year)—+136.2%+113.9%+65.7%+46.9%+53.8%+20.4%+27.7%+20.3%
Gross profit−$13.3M−$6.76M$6.96M$28.7M$51.7M$84.2M$89.7M$133.3M$191.0M
Gross margin−123.1%−26.6%12.8%31.8%39.1%41.4%36.6%42.6%50.7%
Operating income−$58.5M−$70.6M−$108.8M−$140.1M−$152.7M−$234.8M−$217.2M−$220.8M−$136.3M
Operating margin−543.2%−277.5%−200.1%−155.5%−115.4%−115.3%−88.6%−70.6%−36.2%
Net income−$59.3M−$71.2M−$107.7M−$139.9M−$152.1M−$217.9M−$204.6M−$208.7M−$77.7M
Net margin−550.8%−280.2%−198.0%−155.3%−114.9%−107.0%−83.5%−66.7%−20.6%
EPS (diluted)−$24.49−$25.51−$3.92−$3.57−$3.15−$4.04−$3.60−$3.60−$1.30
Balance sheet
Cash and equivalents$31.2M$80.8M$46.7M$93.7M$465.8M$378.7M$286.5M$226.3M$183.0M
Total assets—$115.8M$187.0M$398.9M$702.1M$961.4M$776.4M$614.3M$641.9M
Total liabilities—$26.7M$34.9M$62.6M$121.3M$172.0M$153.0M$141.6M$168.9M
Long-term debt—$7.22M$4.40M$1.40M—————
Shareholders' equity−$133.4M−$201.4M$152.1M$336.3M$580.8M$789.4M$623.4M$472.7M$473.0M
Cash flow
Operating cash flow−$51.3M−$66.2M−$87.9M−$142.3M−$112.2M−$124.4M−$142.5M−$64.1M−$47.6M
Capital expenditure$6.59M$3.69M$14.8M$9.87M$27.1M$101.9M$27.8M$5.08M$28.0M
Free cash flow−$57.9M−$69.9M−$102.7M−$152.1M−$139.3M−$226.2M−$170.3M−$69.2M−$75.6M

From Twist Bioscience Corp's 10-K and 10-Q filings with the SEC; its fiscal year ends in September. Each period shows the latest figure the company has reported for it, including restatements. Net margin is our own calculation from those reported figures (net income ÷ revenue); it is left blank where revenue is zero or missing. † Quarter derived from the company's year-to-date or full-year totals. Filings on SEC EDGAR →

About Twist Bioscience Corp

Headquarters
South San Francisco, California From SEC filings, Oct 2026

Recent News (2)

More Health Care stocks

Browse all companies →